Article Text

Download PDFPDF
Safety and effectiveness of vascular endoprosthesis for malignant superior vena cava syndrome
  1. N P Nguyen1,
  2. T L Borok2,
  3. J Welsh1,
  4. V Vinh-Hung3
  1. 1
    Department of Radiation Oncology, University of Arizona, Tucson, Arizona, USA
  2. 2
    Radiation Oncology Service, Thomas Louis Borok M.D. P.A., Dallas, Texas, USA
  3. 3
    Oncology Centre, Academic Hospital VUB, Jette, Belgium
  1. Dr N P Nguyen, University of Arizona, Department of Radiation Oncology, N Campbell Ave, PO Box 245081, Tucson, AZ 85724-5081, USA; NamPhong.Nguyen{at}


Background: Superior vena cava syndrome management has been traditionally radiation therapy, chemotherapy or chemoradiation, depending on the underlying malignancy involved and individual clinicopathological features of the case. Recent emergence of endovascular stents offer the opportunity for immediate relief of the venous stenosis. This review examines findings from the published series which used endovascular prosthesis for this syndrome with regards to efficacy and safety.

Methods: Literature search identified studies using endovascular stents as initial therapy or for recurrence of malignant superior vena cava syndrome. Effectiveness and toxicity from stent placement was assessed.

Results: Endovascular stent placement provides immediate haemodynamic relief of venous compression either before or after definitive therapy in the majority of cancer patients. Severe bleedings, cardiopulmonary complications and stent migrations remain significant problems for patient management.

Conclusions: Endovascular prosthesis is an effective modality for malignant superior vena cava syndrome with acceptable morbidity. Prospective studies should be performed to determine the optimal anticoagulation regimen.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.